Home/Filings/4/0001856369-25-000016
4//SEC Filing

Gibson Christopher 4

Accession 0001856369-25-000016

CIK 0001601830other

Filed

Dec 4, 7:00 PM ET

Accepted

Dec 5, 7:20 PM ET

Size

23.1 KB

Accession

0001856369-25-000016

Insider Transaction Report

Form 4
Period: 2025-12-04
Transactions
  • Conversion

    Class A Common Stock

    2025-12-04+60,000973,839 total
  • Sale

    Class A Common Stock

    2025-12-04$4.63/sh40,000$185,200933,839 total
  • Gift

    Class A Common Stock

    2025-12-0420,000913,839 total
  • Conversion

    Class B Common Stock

    2025-12-0460,0004,763,334 total
    Exercise: $0.00Class A Common Stock (60,000 underlying)
Holdings
  • Class B Common Stock

    (indirect: By LLC)
    Exercise: $0.00Class A Common Stock (0 underlying)
    386,000
  • Class B Common Stock

    (indirect: By LLC)
    Exercise: $0.00Class A Common Stock (0 underlying)
    388,000
  • Class B Common Stock

    (indirect: By Trust)
    Exercise: $0.00Class A Common Stock (0 underlying)
    50,000
  • Stock Option (Right to Buy)

    Exercise: $10.09Exp: 2034-02-09Class A Common Stock (0 underlying)
    666,898
  • Stock Option (Right to Buy)

    Exercise: $7.25Exp: 2035-02-03Class A Common Stock (0 underlying)
    1,050,567
  • Stock Option (Right to Buy)

    Exercise: $8.55Exp: 2033-02-01Class A Common Stock (0 underlying)
    813,600
  • Stock Option (Right to Buy)

    Exercise: $11.40Exp: 2032-02-04Class A Common Stock (0 underlying)
    399,002
  • Stock Option (Right to Buy)

    Exercise: $11.40From: 2022-02-04Exp: 2032-02-04Class A Common Stock (0 underlying)
    5,436
  • Stock Option (Right to Buy)

    Exercise: $2.48Exp: 2030-12-30Class A Common Stock (0 underlying)
    282,500
Footnotes (10)
  • [F1]Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
  • [F10]The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
  • [F2]This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
  • [F3]The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
  • [F4]The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
  • [F5]The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
  • [F6]The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
  • [F7]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
  • [F8]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
  • [F9]The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

Issuer

RECURSION PHARMACEUTICALS, INC.

CIK 0001601830

Entity typeother

Related Parties

1
  • filerCIK 0001856369

Filing Metadata

Form type
4
Filed
Dec 4, 7:00 PM ET
Accepted
Dec 5, 7:20 PM ET
Size
23.1 KB